查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813989

遗传性癌症检测市场规模、份额和趋势分析报告：按癌症类型、技术、检测类型、最终用途、地区和细分市场预测，2025-2033 年

Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

遗传性癌症检测市场摘要

预计 2024 年全球遗传性癌症检测市值为 46.7 亿美元，2033 年将达到 144.5 亿美元，2025 年至 2033 年的复合年增长率为 13.76%。

由于癌症检测基因检测技术的进步、与精准医疗的结合以及公众和政府措施的提高，对遗传性癌症检测的需求正在增加。

此外，癌症盛行率的上升也推动了遗传性癌症检测的普及。根据美国国家癌症美国的数据，遗传性癌症是由基因变异引起的，占所有其他癌症类型的10%。遗传性癌症透过遗传性突变遗传，导致基因缺陷，并遗传给后代，增加罹癌风险。因此，大众对早期发现和缓解症状的需求日益增长。

基因检测技术的进步，尤其是次世代定序仪(NGS) 技术，显着提高了遗传性癌症检测的准确性和可近性。传统方法效率低且耗时，可能会延长后续治疗时间。次世代定序仪(NGS) 就是这样一种检测技术，它可以在短时间内同时检测单一基因内数百万个 DNA 拷贝，从而能够在一次检测中全面分析多个基因和突变。例如，Illumina 的 NovaSeq X 平台可以分析大规模定序数据，并提供用于诊断疾病状态的高通量定序。基因检测的技术创新有助于早期发现遗传性癌症突变，指导个人化治疗方案，并以非侵入性方式监测疾病进展。因此，透过整合早期癌症检测系统，癌症医学将观点从传统检测方法转向先进技术。

基因检测在精准医疗中发挥着至关重要的作用，它能够识别影响癌症风险和治疗结果的基因突变。精准医疗的根本基础是了解特定基因变异对癌症的影响。精准医疗透过根据患者的个别特征量身定制检测和治疗来改变癌症治疗。它可以识别癌症高风险族群，并及早干预以降低风险。它还可以帮助及早发现某些癌症，并准确诊断特定癌症类型。此外，它还可以持续评估治疗效果并进行调整以改善结果。这种个人化方法透过从「一刀切」的治疗方法转向针对患者的有针对性的治疗方法，提高了癌症患者的生存率和生活品质。

公众和政府主导的意识提昇在扩大遗传性癌症检测方面发挥关键作用。例如，作为一项政府倡议，美国国立卫生研究院 (NIH) 于 2024 年 2 月启动了癌症筛检研究网络 (CSRN)，这是一个临床试验网络，旨在评估新的癌症筛检技术，推出多癌症种检测 (MCD)。该倡议重点关注癌症的早期发现，以便在治疗更有效的时期进行，从而支持拜登-哈里斯政府的「癌症登月计画」。

美国国立卫生研究院 (NIH) 也持续致力于透过预防和筛检五大癌症（乳癌、子宫颈癌、大肠癌、肺癌和摄护腺癌）来挽救生命。截至 2024 年 12 月，这些努力已挽救了 475 万人的生命。此外，多项宣传活动和线上资源也提高了公众对遗传性癌症检测的认识。这些共同努力旨在教育个人、鼓励及时检测并支持预防性护理，最终降低癌症发病率并改善不同人群的预后。

目录

第一章调查方法与范围

第二章执行摘要

3. 遗传性癌症检测市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场前景。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 遗传性癌症检测市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章遗传性癌症检测市场：癌症估计与趋势分析

  • 细分仪表板
  • 遗传性癌症检测市场：癌症变异分析
  • 遗传性癌症检测市场规模及趋势分析（依癌症类型，2021-2033）
  • 2021-2033年遗传性癌症检测市场收益估计与预测
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 卵巢癌
  • 摄护腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宫癌
  • 胰臟癌
  • 其他的

第五章：遗传性癌症检测市场：技术评估与趋势分析

  • 2024年及2033年技术市场份额
  • 细分仪表板
  • 全球遗传性癌症检测市场技术展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 细胞遗传学
  • 生化
  • 分子检测

第六章：遗传性癌症检测市场：检测类型估计与趋势分析

  • 2024 年和 2033 年测试类型市场份额
  • 细分仪表板
  • 全球测试类型市场展望（按数量）
  • 2021年至2033年市场规模、预测与趋势分析
  • 预测测试
  • 诊断测试

7. 遗传性癌症检测市场：最终用途估计与趋势分析

  • 2024年和2033年的最终用途市场份额
  • 细分仪表板
  • 全球最终用途市场：最终用途展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 诊断中心
  • 医院
  • 诊所

第八章：遗传性癌症检测市场：区域估计和趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2021-2033年：
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-588-5

Hereditary Cancer Testing Market Summary

The global hereditary cancer testing market size was estimated at USD 4.67 billion in 2024 and is projected to reach USD 14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine, and growing awareness through public and government initiatives.

In addition, the rising prevalence of cancer diseases amongst the population is augmenting the adoption of hereditary cancer testing. According to the National Cancer Institute, hereditary cancer, caused by inherited genetic changes, accounts for 10% of all other cancer types. Hereditary cancer is passed on to coming generations as defective familial mutations in the genes, concomitantly increasing the risk of cancer. Hence, there arises a growing need among the people for early detection and for mitigating cancer symptoms.

Advancements in genetic testing technologies, particularly next-generation sequencing (NGS), have significantly improved the accuracy and accessibility of hereditary cancer testing. Traditional methods lack efficiency and are time-consuming, which may prolong the treatment duration thereafter. One such testing technology is the next-generation sequencing (NGS), which can simultaneously detect millions of copies of DNA in a gene within a short span of time, allowing comprehensive profiling of multiple genes and mutations in a single test. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of diseases. The innovations in genetic testing facilitate early detection of hereditary cancer mutations, guide personalized treatment plans, and monitor disease progression non-invasively. Thus, progress in oncology medicine by integration of early cancer detection systems is transforming the perspective to advanced technologies rather than traditional testing methods.

Hereditary testing plays a pivotal role in precision medicine by enabling the identification of genetic mutations that influence cancer risk and treatment response. The basis of precision medicine lies in understanding the effects of alterations in certain genes in cancer. Precision medicine is transforming cancer care to tailor tests and treatments based on individual patient characteristics. It helps identify people at high risk for cancer, allowing early interventions to reduce their risk. It also aids in detecting certain cancers at an early stage and ensures accurate diagnosis of specific cancer types. Additionally, it allows ongoing evaluation of how well a treatment is working, enabling adjustments to improve outcomes. This personalized approach improves survival rates and quality of life for cancer patients by moving beyond one-size-fits-all therapies to targeted, patient-specific care.

Growing awareness through public and government initiatives plays a crucial role in expanding hereditary cancer testing. Government efforts, for example, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), a clinical trials network aimed at evaluating emerging cancer screening technologies, including multi-cancer detection (MCD) tests. This initiative supports the Biden-Harris administration's Cancer Moonshot by focusing on identifying cancers earlier, when treatment is more effective.

The National Institutes of Health (NIH) is also working continuously in prevention and screening for five major types of cancer: breast, cervical, colorectal, lung, and prostate, in order to save lives. Due to its initiatives, as of December 2024, 4.75 million deaths have been averted. Furthermore, several campaigns and online resources have raised awareness among the people for hereditary cancer testing. These combined efforts aim to empower individuals with knowledge, encourage timely testing, and support preventive care, ultimately reducing cancer incidence and improving outcomes across diverse populations.

Global Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary cancer testing market report based on cancer, technology, test type, end use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Stomach/Gastric Cancer
  • Melanoma
  • Sarcoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Predictive Testing
  • Diagnostic Testing
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Centers
  • Hospitals
  • Clinics
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
  • 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Myriad Genetics, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Invitae Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Qiagen NV
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Abbott Laboratories
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. EUROFINS SCIENTIFIC
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. F. HOFFMANN-LA ROCHE LTD
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Services benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Illumina, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Services benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Hereditary cancer testing market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 4 North America Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 6 North America Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 8 U.S Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 9 U.S Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 10 U.S Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 12 Canada Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 13 Canada Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 14 Canada Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 16 Mexico Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 20 Europe Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 21 Europe Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 22 Europe Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 23 UK Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 24 UK Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 25 UK Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 26 UK Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Germany Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 28 Germany Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Germany Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 31 France Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 32 France Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 33 France Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 34 France Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Italy Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 36 Italy Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 37 Italy Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 38 Italy Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Spain Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 40 Spain Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 41 Spain Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Spain Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Denmark Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 44 Denmark Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 45 Denmark Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Sweden Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 48 Sweden Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 49 Sweden Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 50 Sweden Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Norway Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 52 Norway Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 53 Norway Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 54 Norway Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Japan Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 60 Japan Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 61 Japan Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 62 Japan Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 63 China Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 64 China Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 China Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 66 China Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 67 India Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 68 India Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 India Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 70 India Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Australia Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 72 Australia Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Australia Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 74 Australia Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Korea Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 76 South Korea Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 South Korea Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 78 South Korea Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Thailand Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 80 Thailand Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Thailand Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 82 Thailand Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Latin America Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 84 Latin America Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Latin America Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 86 Latin America Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 87 Brazil Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 88 Brazil Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Brazil Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 90 Brazil Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Argentina Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 92 Argentina Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 93 Argentina Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 94 Argentina Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 95 MEA Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 96 MEA Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 97 MEA Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 98 MEA Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 99 South Africa Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 100 South Africa Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 101 South Africa Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 102 South Africa Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 Saudi Arabia Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 104 Saudi Arabia Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 105 Saudi Arabia Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 106 Saudi Arabia Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 107 UAE Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 108 UAE Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 109 UAE Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 110 UAE Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 111 Kuwait Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 112 Kuwait Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 113 Kuwait Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 114 Kuwait Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Hereditary cancer testing market: market outlook
  • Fig. 14 Hereditary cancer testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Hereditary cancer testing market driver impact
  • Fig. 20 Hereditary cancer testing market restraint impact
  • Fig. 21 Hereditary cancer testing market strategic initiatives analysis
  • Fig. 22 Hereditary cancer testing market: Cancer movement analysis
  • Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig. 24 Hereditary cancer Testing market estimates and forecast, 2021 - 2033
  • Fig. 25 Hereditary cancer testing Market: Technology movement analysis
  • Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig. 27 Cytogenetic market estimates and forecasts, 2021 - 2033
  • Fig. 28 Biochemical market estimates and forecasts,2021 - 2033
  • Fig. 29 Molecular Testing market estimates and forecasts,2021 - 2033
  • Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig. 32 Predictive Testing market estimates and forecasts, 2021 - 2033
  • Fig. 33 Diagnostic Testing market estimates and forecasts, 2021 - 2033
  • Fig. 34 Hereditary cancer testing Market: End Use movement analysis
  • Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig. 36 Diagnostic Centers market estimates and forecasts, 2021 - 2033
  • Fig. 37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 38 Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 39 Global Hereditary cancer testing market: Regional movement analysis
  • Fig. 40 Global Hereditary cancer testing market: Regional outlook and key takeaways
  • Fig. 41 Global Hereditary cancer testing market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America
  • Fig. 49 North America market estimates and forecasts, 2021 - 2033
  • Fig. 50 U.S.
  • Fig. 51 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 52 Canada
  • Fig. 53 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 54 Mexico
  • Fig. 55 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 56 Europe
  • Fig. 57 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 58 UK
  • Fig. 59 UK market estimates and forecasts, 2021 - 2033
  • Fig. 60 Germany
  • Fig. 61 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 62 France
  • Fig. 63 France market estimates and forecasts, 2021 - 2033
  • Fig. 64 Italy
  • Fig. 65 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 66 Spain
  • Fig. 67 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 68 Denmark
  • Fig. 69 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 70 Sweden
  • Fig. 71 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 72 Norway
  • Fig. 73 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 74 Asia Pacific
  • Fig. 75 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 76 China
  • Fig. 77 China market estimates and forecasts, 2021 - 2033
  • Fig. 78 Japan
  • Fig. 79 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 80 India
  • Fig. 81 India market estimates and forecasts, 2021 - 2033
  • Fig. 82 Thailand
  • Fig. 83 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 84 South Korea
  • Fig. 85 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 86 Australia
  • Fig. 87 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 88 Latin America
  • Fig. 89 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 90 Brazil
  • Fig. 91 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 92 Argentina
  • Fig. 93 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 94 Middle East and Africa
  • Fig. 95 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 96 South Africa
  • Fig. 97 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 98 Saudi Arabia
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 100 UAE
  • Fig. 101 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 102 Kuwait
  • Fig. 103 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 104 Market share of key market players- Hereditary cancer testing market